Evidence map›Paper›PMID 28835536›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2017

Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts.

Rita Fior, Vanda Póvoa, Raquel V Mendes, Tânia Carvalho, António Gomes, Nuno Figueiredo, Miguel Godinho Ferreira

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05289076 (Protocol for Evaluation of Oncological Treatment in Patients With CRLM Using Zebra Fish Avatars-may This Model Improve Resection Rates and Survival in Patients With Upfront Non-resectable Metastatic Disease?), which is not on this map. Cited by 203 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
203citing papers in PubMed, 1 pooled it
12.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05289076 phase1 / phase2unknown statusnot on this mapstarted 2022, after this paper: background citation

Protocol for Evaluation of Oncological Treatment in Patients With CRLM Using Zebra Fish Avatars-may This Model Improve Resection Rates and Survival in Patients With Upfront Non-resectable Metastatic Disease?

TypeinterventionalSponsorUniversity Hospital, LinkoepingRan2022 to 2025Enrolled40ConditionsColorectal Cancer Metastatic, Tumour Metastasis, Chemotherapy Effect, Tumor GrowthArmsChemotherapy drug
3 · Its place in the literature

Who cites it

203 citing papers in PubMed, 1 synthesis or guideline pooled it, 325 citations in OpenAlex.

  1. Pooled it
  2. Using Zebrafish Larvae as a Xenotransplantation Model to Study Ewing Sarcoma.Methods in molecular biology (Clifton, N.J.) · 2027
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Choosing the right animal model for sarcoma research.Cellular and molecular life sciences : CMLS · 2026
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Zebrafish as a Model for Translational Immuno-Oncology.Journal of personalized medicine · 2025
    Review

143 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Rita FiorChampalimaud Centre for the Unknown, 1400-038 Lisbon, Portugal; rita.fior@neuro.fchampalimaud.org miguel.ferreira@research.fchampalimaud.org.
Vanda PóvoaChampalimaud Centre for the Unknown, 1400-038 Lisbon, Portugal.
Raquel V MendesChampalimaud Centre for the Unknown, 1400-038 Lisbon, Portugal.
Tânia CarvalhoInstituto de Medicina Molecular, Universidade de Lisboa, 1649-028 Lisboa, Portugal.
António GomesHospital Prof. Doutor Fernando Fonseca, 2720-276 Amadora, Portugal.
Nuno FigueiredoChampalimaud Clinical Center, 1400-038 Lisboa, Portugal.
Miguel Godinho FerreiraChampalimaud Centre for the Unknown, 1400-038 Lisbon, Portugal; rita.fior@neuro.fchampalimaud.org miguel.ferreira@research.fchampalimaud.org.ORCID 0000-0002-8363-7183
Champalimaud Foundation · PTHospital Prof. Dr. Fernando Fonseca · PTUniversity of Lisbon · PT

Funding

Howard Hughes Medical Institute
6 · The paper itself

Abstract

Cancer is as unique as the person fighting it. With the exception of a few biomarker-driven therapies, patients go through rounds of trial-and-error approaches to find the best treatment. Using patient-derived cell lines, we show that zebrafish larvae xenotransplants constitute a fast and highly sensitive in vivo model for differential therapy response, with resolution to reveal intratumor functional cancer heterogeneity. We screened international colorectal cancer therapeutic guidelines and determined distinct functional tumor behaviors (proliferation, metastasis, and angiogenesis) and differential sensitivities to standard therapy. We observed a general higher sensitivity to FOLFIRI [5-fluorouracil(FU)+irinotecan+folinic acid] than to FOLFOX (5-FU+oxaliplatin+folinic acid), not only between isogenic tumors but also within the same tumor. We directly compared zebrafish xenografts with mouse xenografts and show that relative sensitivities obtained in zebrafish are maintained in the rodent model. Our data also illustrate how

Indexed as

AnimalsAntineoplastic Combined Chemotherapy ProtocolsCamptothecinColorectal NeoplasmsFemaleFluorouracilHumansIrinotecanLeucovorinMiceMice, Inbred NODMice, SCIDOrganoplatinum CompoundsOxaliplatinXenograft Model Antitumor AssaysZebrafishCamptothecinFluorouracilIrinotecanLeucovorinOrganoplatinum CompoundsOxaliplatinchemotherapy functional screeningcolorectal cancerKRASpatient derived xenograftszebrafish xenograft

Identifiers

PMID28835536
PMCPMC5625889
OpenAlexW2748052555

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.